Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

John Radford, Joanna Williams, Darren Edwards, Ruth Pettengell, Peter Johnson, Peter Hoskin, Timothy Illidge, Nicholas Counsell

Blood (2024) 144 (Supplement 1): 457.

https://doi.org/10.1182/blood-2024-200662

Published: 2024

Journal Articles

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema, Neil K Rabin, Shirley D'Sa, Graham Jackson, Peter Hoskin, Eve Gallop-Evans, Patricia Diez, Catherine Parbutt, Andre Lopes, Sevasti Galani, Laura Clifton-Hadley, Darren Edwards, Husne Timur Tezver, Ruth M. de Tute, Andrew Bates, Roger G Owen

Blood (2022) 140 (Supplement 1): 12626–12627.

https://doi.org/10.1182/blood-2022-158528

Published: 2022

Journal Articles

Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, PhD, Susan K Parsons, MD MRP, Carlton Scharman, MD, Ranjana Advani, MD, Massimo Federico, MD, Jonathan W. Friedberg, MD MSSc, Andrea Gallamini, MD, David C. Hodgson, MD MPH, FRCPC, Peter Hoskin, MD, Martin Hutchings, MD PhD, Peter Johnson, MD FRCP, Kara M. Kelly, MD, Brian K. Link, MD, John A. Radford, MD FMedSci, Pier Luigi Zinzani, MD, James R. Cerhan, MD PhD, John Raemaekers, MD, Andrew M. Evens, DO,MMSc, On Behalf Of The HoLISTIC Consortium

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-135935

Published: 2020

Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

John Radford, Sally Barrington, Nicholas Counsell, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Stewart Coltart, Dominic Culligan, Andrew Lister, Eric Bessell, Anton Kruger, Bilyana Popova, Barry Hancock, Peter Hoskin, Timothy Illidge, Michael O'Doherty

Blood (2012) 120 (21): 547.

https://doi.org/10.1182/blood.V120.21.547.547

Published: 2012

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

Peter W.M. Johnson, MD, FRCP, Alan Horwich, PhD, FRCR, MRCP, Andrew Jack, MD, FRCPath, Graham Mead, DM, FRCP, Barry Hancock, MD, FRCP, Paul Smith, Wendi Qian, Philippa Patrick, PhD, Andrew Pettitt, David Cunningham, Peter Hoskin, MD, FRCR

Blood (2008) 112 (11): 370.

https://doi.org/10.1182/blood.V112.11.370.370

Published: 2008

Journal Articles

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.

Sally F Barrington, Michael J O’Doherty, Jane MacKewn, Paul Schleyer, Wendi Qian, Philippa Patrick, Timothy Illidge, Ruth Pettengell, Peter Hoskin, Barry Hancock, John Radford

Blood (2008) 112 (11): 1449.

https://doi.org/10.1182/blood.V112.11.1449.1449

Published: 2008

Journal Articles

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

John Radford, Michael O’Doherty, Sally Barrington, Wendi Qian, Philippa Patrick, Stewart Coltart, Dominic Culligan, Jennie Wimperis, Eric Bessell, David Linch, Peter Johnson, David Cunningham, T. Andrew Lister, Peter Hoskin, Ruth Pettengell, Barry Hancock, Timothy Illidge

Blood (2008) 112 (11): 369.

https://doi.org/10.1182/blood.V112.11.369.369

Published: 2008

Journal Articles

Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.

Peter Johnson, MD, Peter Hoskin, MD, Alan Horwich, MD, Barry Hancock, MD, Paul Smith, Lindsey Stevens, Wendy Qian, John William Sweetenham, MD

Blood (2004) 104 (11): 311.

https://doi.org/10.1182/blood.V104.11.311.311

Published: 2004

Journal Articles

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

Paul N. Mainwaring, David Cunningham, Walter Gregory, Peter Hoskin, Barry Hancock, Andrew J. Norton, Ken MacLennan, Paul Smith, Gillian Vaughan Hudson, David Linch

Blood (2001) 97 (10): 2991–2997.

https://doi.org/10.1182/blood.V97.10.2991

Published: 2001

NARROW

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy.

Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.

Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only